X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to support Autolus in the development of BNT211 (CLDN6 CAR-T/CLDN6 CAR-T(A)) for the treatment of relapsed or refractory advanced solid tumors such as ovarian cancer, sarcoma, testicular cancer, endometrial cancer and gastric cancer.
Lead Product(s): BNT211,CARVac
Therapeutic Area: Oncology Product Name: BNT211
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BioNTech
Deal Size: $250.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration February 08, 2024
Details:
AUTO1 (obecabtagene autoleucel) is a CD19 CAR T cell investigational therapy. It is being evaluated in phase 1/2 clinical trials for the treatment of relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia.
Lead Product(s): Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: AUTO1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
AUTO1 (obecabtagene autoleucel) is an autologous CD19 CAR T cell therapy with a unique CD19 CAR. The CAR is designed to have a fast-off kinetic which mimics physiological T-cell receptor interactions.
Lead Product(s): Obecabtagene Autoleucel
Therapeutic Area: Oncology Product Name: AUTO1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 08, 2022
Details:
Obe-cel (AUTO1), is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.
Lead Product(s): Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: AUTO1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
This follows an original agreement with Moderna, granting Moderna an exclusive option to license Autolus’ proprietary binders for up to four immuno-oncology targets for incorporation in certain mRNA therapeutics.
Lead Product(s): mRNA-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2022
Details:
Under the terms of the agreement, Autolus will receive payment for access to the RQR8 safety switch for the initial set of cell therapy programs with the potential for near term option exercise fees and development milestone payments.
Lead Product(s): CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 04, 2022
Details:
AUTO4 is a programmed T cell product candidate in clinical development for T cell lymphoma, a setting where there are currently no approved programmed T cell therapies.
Lead Product(s): AUTO4,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: AUTO4
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Obecabatagene autoleucel, a CD19-directed autologous CAR-T therapy, reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve ability of programmed T cells to engage in serial killing of target cancer cells.
Lead Product(s): Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: AUTO1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL.
Lead Product(s): Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Obe-cel
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
Obecabtagene Autoleucel (Obe-cel) is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies used in adult ALL and B-NHL.
Lead Product(s): Obecabtagene Autoleucel
Therapeutic Area: Oncology Product Name: Obe-cel
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Blackstone Life Sciences
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
